medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2013, Número 1

<< Anterior Siguiente >>

Ann Hepatol 2013; 12 (1)


Hepatic venous pressure gradient measurement in pre-primary and primary prophylaxis of variceal hemorrhage

Vorobioff JD, Groszmann RJ

Idioma: Ingles.
Referencias bibliográficas: 67
Paginas: 22-29
Archivo PDF: 108.97 Kb.


RESUMEN

Sin resumen.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Vorobioff J. Hepatic venous pressure in practice. How, when and why. J Clin Gastroenterol 2007; 41(Supp. 3): S336-S343.

  2. Groszmann RJ, García Tsao G, Bosch J, Grace ND, Burroughs AK, Planas R, Escorsell A, et al. Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis. N Engl J Med 2005; 353: 2254-61.

  3. Merkel C, Marin R, Angeli P, Zanella P, Felder M, Bernardinello E, Cavallarin G, et al. A placebo-controlled clinical trial of nadolol in the prophylaxis of growth of small esophageal varices in cirrhosis. Gastroenterology 2004; 127: 476-84.

  4. Ripoll C, Groszmann RJ, García-Tsao G, Grace ND, Burroughs AK, Planas R, Escorsell A, et al. Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis. Gastroenterology 2007; 133: 481-8.

  5. Ripoll C, Groszmann RJ, García-Tsao G, Bosch J, Grace ND, Burroughs AK, Planas R, et al. Hepatic venous pressure gradient predicts development of hepatocellular carcinoma independently of severity of cirrhosis. J Hepatol 2009; 50: 923-8.

  6. Groszmann RJ, Bosch J, Grace N, Conn HO, Garcia-Tsao G, Navasa M, Alberts J, et al. Hemodynamic events in a prospective randomized trial of propranolol versus placebo in the prevention of a first variceal hemorrhage. Gastroenterology 1990; 99: 1401-7.

  7. Merkel C, Bolognesi M, Bellon S, Zuin R, Noventa F, Finucci G, Sacerdoti D, et al. Prognostic usefulness of hepatic vein catheterization in patients with cirrhosis and esophageal varices. Gastroenterology 1992; 102: 973-9.stratification by continuous portal pressure monitoring during acute variceal bleeding. Gastroenterology 2001; 121: 110-17.

  8. Feu F, García-Pagán JC, Bosch J, Luca A, Escorsell A, Rodés J, Terés J, et al. Relation between portal pressure response to pharmacotherapy and risk of recurrent variceal hemorrhage in patients with cirrhosis. Lancet 1995; 346: 1056-9.

  9. Vorobioff J, Groszmann RJ, Picabea E, Gamen M, Villavicencio R, Bordato J, Morel I, et al. Prognostic value of hepatic venous pressure gradient measurements in alcoholic cirrhosis: A 10-year prospective study. Gastroenterology 1996; 111: 701-9.

  10. D’Amico G, Pagliaro L, Bosch J. Pharmacological treatment of portal hypertension: an evidence-based approach. Semin Liver Dis 1999; 19: 475-505.

  11. D’Amico G, García-Pagán JC, Luca A, Bosch J. Hepatic vein pressure gradient reduction and prevention of variceal bleeding in cirrhosis: a systematic review. Gastroenterology 2006; 131: 1611-24.

  12. Abraldes JG, Tarantino I, Turnes J, García-Pagan JC, Rodés J, Bosch J. Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhosis. Hepatology 2003; 37: 902-8.

  13. Villanueva C, López-Balaguer JM, Aracil C, Kolle L, González B, Miñana J, Soriano G, et al. Maintenance of hemodynamic response to treatment for portal hypertension and influenece on complications of cirrhosis. J Hepatol 2004; 40: 757-65.

  14. Turnes J, García-Pagán JC, Abraldes J, Hernández-Guerra L, Dell’Era A, Bosch J. Pharmacological reduction of portal pressure and long-term risk of first variceal bleeding in patients with cirrhosis. Am J Gastro 2006; 101: 506-12.

  15. Vinel JP, Cassigneul J, Levade M, Voigt JJ, Pascal P. Assessment of short-term prognosis after variceal bleeding in patients with alcoholic cirrhosis by early measurement of portohepatic gradient. Hepatology 1986; 6: 116-17.

  16. Moitinho E, Escorsell A, Bandi JC, Salmerón JM, García-Pagán JC, Rodés J, Bosch J. Prognostic value of early measurements of portal pressure in acute variceal bleeding. Gastroenterology 1999; 117: 626-31.

  17. Villanueva C, Ortiz J, Miñana J, Soriano G, Sàbat M, Boadas J, Balanzó J. Somatostatin treatment and risk stratification by continuous portal pressure monitoring during acute variceal bleeding. Gastroenterology 2001; 121: 110-17.

  18. Monescillo A, Martínez-Lagares F, Ruiz-del-Arbol L, Sierra A, Guevara C, Jiménez E, Marrero JM, et al. Influence of portal hypertension and its early decompression by TIPS placement on the outcome of variceal bleeding. Hepatology 2004; 40: 793-801.

  19. Bruix J, Castells A, Bosch J, Feu F, Fuster J, García-Pagán JC, Visa J, et al. Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure. Gastroenterology 1996; 111: 1018-22.

  20. Rincon D, Ripoll C, Lo Iacono O, Salcedo M, Catalina MV, Alvarez E, Núñez O, et al. Antiviral therapy decreases hepatic venous pressure gradient in patients with chronic hepatitis C and advanced fibrosis. Am J Gastroenterol 2006; 101: 2269-74.

  21. Carrion JA, Navasa M, García-Retortillo M, García-Pagán JC, Crespo G, Bruguera M, Bosch J, et al. Efficacy of antiviral therapy on hepatitis C recurrence alter liver transplantation: A randomized, controlled study. Gastroenterology 2007; 132: 1746-56.

  22. Gluud C, Brok J, Gong Y, Koretz RL. Hepatology may have problems with putative surrogate outcome measures. J Hepatol 2007; 46: 734-42.

  23. Myers JD, Taylor WJ. An estimation of portal venous pressure by occlusive catheterization of a hepatic venule. J Clin Invest 1951; 30: 662-63.

  24. Groszmann RJ, Glickman MC, Blei AT, Storer E, Conn HO. Wedged and free hepatic venous pressure measured with a balloon catheter. Gastroenterology 1979; 76: 253-58.

  25. Bosch J, Mastai R, Kravetz D, Navasa M, Rodes J. Hemodynamic evaluation in patients with portal hypertension. Semin Liver Dis 1986; 6: 309-17.

  26. Groszmann R, Wongcharatrawee S. The hepatic venous pressure gradient: Anything worth doing should be done right. Hepatology 2004; 39: 280-2.

  27. Zipprich A, Winkler M, Seufferlein T, Dollinger MM. Comparison of balloon vs. straight catheter for the measurement of portal hypertension. Aliment Pharmacol Ther 2010; 32: 1351-56.

  28. Merkel C, Escorsell A, Sieber CC, Lee FY, Groszmann RJ. Pre-primary prophylaxis: Can (and should) we prevent the formation and growth of varices? In: de Franchis R (ed.). Portal Hypertension III. Proceedings of the Third Baveno International Consensus Workshop on Definitions, Methodology and Therapeutic Strategies. Oxford: Blackwell Science; 2001, p. 97-111.

  29. Groszmann RJ, Merkel C, Iwakiri Y, Shah V, Shneider BL, Zoli M, Berzigotti A, et al. Prevention of the formation of varices (Pre-primary prophylaxis). In: de Franchis R (ed.). Portal Hypertension IV. Proceedings of the Fourth Baveno International Consensus Workshop on Methodology of Diagnosis and Treatment. Oxford: Blackwell Science; 2006, p. 103-151.

  30. Calès P, Oberti F, Payen JL, Naveau S, Guyader D, Blanc P, Abergel A, et al. Lack of effect of propranolol in the prevention of large oesophageal varices in patients with cirrhosis: a randomized trial. Eur J Gastroenterol Hepatol 1999; 11: 741-5.

  31. Qamar AA, Groszmann RJ, Grace ND, Garcia-Tsao G, Burroughs AK, Bosch J. Lack of effect of non-selective betablockers on the hepatic venous pressure gradient (HVPG) in patients with mild portal hypertension: a tail of two studies. Hepatology 2010; 52 (Suppl.): 1020 A.

  32. Ferayorni L, Polio J, Groszmann RJ. Drug therapy for portal hypertension: a 5-year review. In: de Franchis R (ed.). Portal Hypertension II. Proceedings of the second Baveno International Consensus Workshop on Definitions, Methodology and Therapeutic Strategies. Oxford: Blackwell Science: 1996, p. 68-99.

  33. Grace ND, Groszmann RJ, García-Tsao G, Burroughs A, Pagliaro L, Makuch RW, Bosch J, et al. Portal hypertension and variceal bleeding: an AASLD single topic syposium. Hepatology 1998; 28: 868-80.

  34. Merkel C, Bolognesi M, Sacerdoti D, Bombonato G, Bellini B, Bighin R, Gatta A. The hemodynamic response to medical treatment of portal hypertension as a predictor of clinical effectiveness in the primary prophylaxis of variceal bleeding in cirrhotic patients. Hepatology 2000; 32: 930-34.

  35. Escorsell A, Bordas JM, Castañeda B, Llach J, García-Pagán JC, Rodés J, Bosch J. Predictive value of the variceal pressure response to continued pharmacological therapy in patients with cirrhosis and portal hypertension. Hepatology 2000; 31: 1061-7.

  36. Bureau C, Peron JM, Alric L, Morales J, Sanchez J, Barange K, Payen JL, et al. “A La Carte” treatment of portal hypertension: adapting medical therapy to hemodynamic response for the prevention of bleeding. Hepatology 2002; 36: 1361-6.stratification by continuous portal pressure monitoring during acute variceal bleeding. Gastroenterology 2001; 121: 110-17.

  37. Abraczinskas DR, Ookubo R, Grace ND, Groszmann RJ, Bosch J, García-Tsao G, Richardsdon CR, et al. Propranolol for the prevention of first esophageal variceal hemorrhage: a lifetime commitment? Hepatology 2001; 34: 1096-102.

  38. Bandi JC, García-Pagan JC, Escorsell A, Francois E, Moitinho E, Rodes J, Bosch J. Effects of propranolol on the hepatic hemodynamic response to physical exercise in patients with cirrhosis. Hepatology 1998; 28: 677-82.

  39. Luca A, García-Pagán JC, Bosch J, Feu F, Caballeria J, Groszmann RJ, Rodes J. Effects of ethanol consumption on hepatic hemodynamics in patients with alcoholic cirrhosis. Gastroenterology 1997; 112: 1284-89.

  40. Vorobioff J, Gamen M, Kravetz D, Picabea E, Villavicencio R, Bordato J, Ruf A, et al. Effects of long-term propranolol and octreotide on postprandial hemodynamics in cirrhosis: A randomized, controlled trial. Gastroenterology 2002; 122: 916-22.

  41. Polio J, Groszmann RJ. Hemodynamic factors involved in the development and rupture of esophageal varices: a pathophysiologic approach to treatment. Semin Liver Dis 1986; 4: 318-31.

  42. Albillos A, García-Pagán JC, Iborra J, Bandi JC, Cacho G, Perez-Paramo M, Escorsell A, et al. Propranolol plus prazosin compared with propranolol plus isosorbide-5-mononitrate in the treatment of portal hypertension. Gastroenterology 1998; 115: 116-23.

  43. Bañares R, Moitinho E, Matilla A, García-Pagán JC, Lampreave JL, Piera C, Abraldes JG, et al. Randomized comparison of long-term carvedilol and propranolol administration in the treatment of portal hypertension in cirrhosis. Hepatology 2002; 36: 1367-73.

  44. Abraldes JG, Albillos A, Bañares R, Turnes J, González R, García-Pagán JC, Bosch J. Simvastatin lowers portal pressure in patients with cirrosis and portal hypertension: A randomized controlled trial. Gastroenterology 2009; 136: 1651-58.

  45. Zipprich A, Loureiro-Silva M, D’Silva I, Groszmann RJ. The role of hepatic arterial flow on portal venous and hepatic venous wedged pressure in the isolated perfused CCl4-cirrhotic liver. Am J Physiol Gastrointest Liver Physiol 2008; 295: G197-G202.

  46. Pomier-Layrargues G, Kusielewicz D, Willems B, Villeneuve JP, Marleau D, Coté J, Huet PM. Presinusoidal portal hypertension in non-alcoholic cirrhosis. Hepatology 1985; 5: 415-18.

  47. Perelló A, Escorsell A, Bru C, Gilabert R, Moitinho E, García- Pagán JC, Bosch J. Wedged hepatic venous pressure adequately reflects portal pressure in hepatitis C virus-related cirrhosis. Hepatology 1999; 30: 1393-97.

  48. La Mura V, Abraldes JG, Raffa S, Retto O, Berzigotti A, García-Pagán JC, Bosch J. Prognostic value of acute hemodynamic response to i.v. propranolol in patients with cirrhosis and portal hypertension. J Hepatol 2009; 51: 279-87.

  49. Villanueva C, Aracil C, Colomo A, Hernández-Gea V, López- Balaguer JM, Alvarez-Urturi C, Torras X, et al. Acute hemodynamic response to β-blockers and prediction of long-term outcome in primary prophylaxis of variceal bleeding. Gastroenterology 2009; 137: 119-28.

  50. Vorobioff J, Picabea E, Villavicencio R, Puccini V, Rossi O, Bordato J, Audano M. Acute and chronic hemodynamic effects of propranolol in unselected cirrhotic patients. Hepatology 1987; 7: 648-53.

  51. Merkel C, Bolognesi M, Sacerdoti D, Bombonato G, Cavasin L, Gatta A. Disagreement between acute and chronic hemodynamic effects of nadolol in cirrhosis: a pathophysiological interpretation. Aliment Pharmacol Ther 2005; 22: 433-9.

  52. Merkel C, Bolognesi M, Berzigotti A, Amodio P, Cavasin L, Casarotto IM, Zoli M, et al. Clinical significance of worsening portal hypertension during long-term medical treatment in patients with cirrhosis who had been clasified as early good-responders on hemodynamic criteria. J Hepatol 2010; 52: 45-53.

  53. Grace N, García-Pagan JC, Angelico M, Moreau R, Albillos A, Schepke M, Boyer TD, et al. Primary prophylaxis for variceal bleeding. In: de Franchis R (ed.). Portal Hypertension IV. Proceedings of the fourth Baveno International Consensus Workshop on Methodology of Diagnosis and Treatment. Oxford: Blackwell Science; 2006, p. 168-200.

  54. De Franchis R. On behalf of the Baveno V faculty. Revising consensus in portal hypertension: Report of the Baveno V workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol 2010; 53: 762-68.

  55. Merkel C. A short cut to predict the clinical response to beta-blocker therapy in cirrhosis? J Hepatol 2009; 51: 268-70.

  56. Feu F, Bordas JM, Luca A, García-Pagán JC, Escorsell A, Bosch J, Rodes J. Reduction of variceal pressure by propranolol: comparison of the effects on portal pressure and azygos blood flow in patients with cirrhosis. Hepatology 1993; 18: 1082-89.

  57. Pérez-Paramo M, Muñoz J, Albillos A, Freile I, Portero F, Santos M, Ortiz-Berrocal J. Effect of propranolol on the factors promoting bacterial translocation in cirrhotic rats with ascites. Hepatology 2000; 31: 43-48.

  58. Talheimer U, Bosch J, Burroughs A. How to prevent varices from bleeding: Shades of gray-The case for nonselective β-blockers. Gastroenterology 2007; 133: 2029-36.

  59. Garcia-Tsao G, Bosch J, Groszmann RJ. Portal hypertension and variceal bleeding-unresolved issues. Summary of an American Association for the Study of Liver Diseases and European Association for the Study of the Liver Single-Topic Conference. Hepatology 2008; 44: 1764-72.

  60. Vizzutti F, Arena U, Romanelli RG, Rega L, Foschi M, Colagrande S, Petrarca A, et al. Liver stiffness measurement predicts severe portal hypertension in patients with HCVrelated cirrhosis. Hepatology 2007; 45: 1290-7.

  61. Lim JK, Groszmann RJ. Transient Elastography for Diagnosis of Portal Hypertension in Liver Cirrhosis: Is There Still a Role for Hepatic Venous Pressure Gradient Measurement? Hepatology 2007; 45: 1087-90.

  62. Bureau C, Metivier S, Peron JM, Selves J, Robic MA, Gourrauds PA, Rouquet O, et al. Transient elastography accurately predicts presence of significant portal hypertension in patients with chronic liver disease. Aliment Pharmacol Ther 2008; 27: 1261-68.

  63. Lemoine M, Katsahian S, Ziol M, Nahon P, Ganne-Carrie N, Kazemi F, Grando-Lemaire V, et al. Liver stiffness measurement as a predictive tool of clinically significant portal hypertension in patients with compensated hepatitis C virus or alcohol-related cirrhosis. Aliment Pharmacol Ther 2008; 28: 1102-10.

  64. Mejías M, García-Pras E, Tiani C, Miquel R, Bosch J, Fernández M. Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulation in portal hypertensive and cirrhotic rats. Hepatology 2009; 49: 1245-56

  65. Berzigotti A, Bellot P, De Gottardi A, García-Pagán JC, Gagnon C, Spénard, Bosch J. NCX-1000, a nitric oxide-releasing derivative of UDCA, does not decrease portal pressure in patients with cirrhosis: results of a randomized, double-blind, dose-escalating study. Am J Gastroenterol 2009; 105: 1094-101.

  66. Popov Y, Schuppan D. Targeting Liver Fibrosis: Strategies for Development and Validation of Antifibrotic Therapies. Hepatology 2009; 50: 1294-306.

  67. Tsochatzis EA, Bosch J, Burroughs A. A new therapeutic paradigm for patients with cirrhosis. Hepatology 2012. Accepted Article’, Doi: 10.1002/hep.25915 (In press).




2020     |     www.medigraphic.com